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Introduction: Despite advanced therapies for pulmonary arterial hypertension (PAH), maternal mor-
tality in women with PAH and their offspring remains high (30-56% and 11-28%) and is especially high 
during the post-partum period1,2.
Case report: 39-years-old woman was presented in 24th week of pregnancy with moderate dyspnea and 
cyanosis without peripheral edema. ECG showed right ventricular strain and NT-proBNP was 1300 ng/L. 
Echocardiogram showed severe precapillary pulmonary hypertension with systolic pulmonary pressure 
(PAP) 103 mmHg, reduced stroke volume (SVI 29 ml/m2), normal cardiac output (CI 2.6 L/min/m2) and 
mildly reduced systolic function of the right ven-
tricle (FAC 30%, PMI TDI 0.8) with normal central 
venous pressure (CVP) 3 mmHg. Right heart 
catheterization confirmed echocardiographic 
hemodynamic measurements (mean pulmo-
nary pressure 61 mmHg, pulmonary vascular 
resistance (PVR) 9.4 WU) and the vasoreactivity 
test was negative. Epoprostenol was initiated, 
titrated up to 22 ng/kg/min and on 30th week 
planned caesarean section was performed with 
NO inhalations, noradrenalin and dobutamine. 
Fortunately, standby supportive therapy - ECMO 
and high urgency lung transplantation, was not 
needed. The baby did well. The patient was extu-
bated on the same day and sildenafil was added. 
The patient was discharged after 4 weeks. After 
2 months epoprostenol was switched to trepro-
stinil up to 26 ng/kg/min and macitentan was 
added. NT-proBNP stabilized at 170 ng/L. Echo-
cardiography was performed weekly to moni-
tor CI, CVP and right systolic function indexes. 
Favorable echocardiographic dynamics after 
therapy were observed: mean PAP 60 mmHg to 
45-50 mmHg, PVR from 10 WU to 7 WU, stroke 
volume normalized and CVP remained normal. 
However, right ventricular systolic function im-
proved but did not normalize (Table 1).
In conclusion, with complete echocardiograph-
ic hemodynamic assessment and thorough 
clinical assessment high-risk pregnancies in 
patients with severe PAH can be managed. In 
addition, FAC, MPI TDI, 3D ejection fraction and 
RV free strain better assess right ventricular 
systolic function than TAPSE. 
TABLE 1. Echocardiography variables before 
and after therapy.
sPAP mmHg 106 64
mPAP mmHg 64 42
PVR (WU) 10 7
RAP mmHg 3 3
SV ml 51 69
SVI ml/m2 29 40
CO L/min 4.6 4.7
CI L/min/m2 2.6 2.7
RA cm2 26 26
RV TAPSE cm 1.8 2.4
RV FAC % 24 30 (3D EF 36%)
RV MPI TDI





LV Eccentricity index 2.4 / 3.9 1.5 / 2.1
Pericardial effusion minimal minimal
sPAP = systolic pulmonary artery pressure, mPAP = mean pul-
monary artery pressure, PVR = pulmonary vascular resistance, 
RAP = right atrial pressure, SV = stroke volume, SVI = stroke volu-
me index, CO = cardiac output, CI = cardiac index, RA = right atrial 
area, RV = right ventricle, TAPSE = tricuspid annular plane systo-
lic excursion, FAC = fractional area change, MPI TDI = myocardial 
performance index, 3D EF = three-dimensional ejection fraction, 
RV free strain = right ventricular free wall longitudinal strain.
